Mirum Pharmaceuticals, Inc. Operating Income
Mirum Pharmaceuticals, Inc. (MIRM) reported Operating Income of -$42.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$42.54M.
- Mirum Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$789.47M.
- Mirum Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$4.57M.
- Mirum Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-09-30 was $2.60M.
- Mirum Pharmaceuticals, Inc. operating income (loss) for fiscal 2025 was -$22.14M.
- Mirum Pharmaceuticals, Inc. operating income (loss) for fiscal 2024 was -$87.61M.
- Mirum Pharmaceuticals, Inc. operating income (loss) for fiscal 2023 was -$109.15M.
- Mirum Pharmaceuticals, Inc. operating income (loss) for fiscal 2022 was -$131.22M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 5 month | Operating Income (Loss) 6 month | Operating Income (Loss) 8 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$42.54M 10-Q · filed 2026-08-05 | -$832.00M 10-Q · filed 2026-08-05 | -$836.57M derived: sum of 3 quarters · filed 2026-08-05 | -$833.97M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$789.47M 10-Q · filed 2026-05-06 | -$794.03M derived: sum of 2 quarters · filed 2026-05-06 | -$791.43M derived: sum of 3 quarters · filed 2026-05-06 | -$796.42M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | -$4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.96M derived: sum of 2 quarters · filed 2026-02-25 | -$6.95M derived: sum of 3 quarters · filed 2026-08-05 | -$22.14M 10-K · filed 2026-02-25 | ||
| 2025-09-30 | $2.60M 10-Q · filed 2025-11-04 | -$2.39M derived: sum of 2 quarters · filed 2026-08-05 | -$17.57M 10-Q · filed 2025-11-04 | -$41.79M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | -$4.99M 10-Q · filed 2026-08-05 | -$20.17M 10-Q · filed 2026-08-05 | -$44.39M derived: sum of 3 quarters · filed 2026-08-05 | -$57.08M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$15.18M 10-Q · filed 2026-05-06 | -$39.41M derived: sum of 2 quarters · filed 2026-05-06 | -$52.09M derived: sum of 3 quarters · filed 2026-05-06 | -$76.32M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$24.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$36.91M derived: sum of 2 quarters · filed 2026-02-25 | -$61.14M derived: sum of 3 quarters · filed 2026-02-25 | -$87.61M 10-K · filed 2026-02-25 | ||
| 2024-09-30 | -$12.68M 10-Q · filed 2025-11-04 | -$36.92M derived: sum of 2 quarters · filed 2025-11-04 | -$63.38M 10-Q · filed 2025-11-04 | -$95.97M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-06-30 | -$24.23M 10-Q · filed 2025-08-06 | -$50.70M 10-Q · filed 2025-08-06 | -$83.28M derived: sum of 3 quarters · filed 2026-02-25 | -$108.43M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | -$26.47M 10-Q · filed 2025-05-07 | -$59.05M derived: sum of 2 quarters · filed 2026-02-25 | -$84.20M derived: sum of 3 quarters · filed 2026-02-25 | -$108.47M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2023-12-31 | -$32.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$57.73M derived: sum of 2 quarters · filed 2026-02-25 | -$82.01M derived: sum of 3 quarters · filed 2026-02-25 | -$109.15M 10-K · filed 2026-02-25 | ||
| 2023-09-30 | -$25.15M 10-Q · filed 2024-11-12 | -$49.42M derived: sum of 2 quarters · filed 2024-11-12 | -$76.57M 10-Q · filed 2024-11-12 | -$110.73M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | -$24.27M 10-Q · filed 2024-08-07 | -$51.42M 10-Q · filed 2024-08-07 | -$85.58M derived: sum of 3 quarters · filed 2025-02-26 | -$118.46M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | -$27.15M 10-Q · filed 2024-05-08 | -$61.31M derived: sum of 2 quarters · filed 2025-02-26 | -$94.19M derived: sum of 3 quarters · filed 2025-02-26 | -$125.63M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | -$34.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$67.04M derived: sum of 2 quarters · filed 2025-02-26 | -$98.48M derived: sum of 3 quarters · filed 2025-02-26 | -$131.22M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | -$32.88M 10-Q · filed 2023-11-02 | -$64.32M derived: sum of 2 quarters · filed 2023-11-02 | -$97.06M 10-Q · filed 2023-11-02 | -$142.63M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-06-30 | -$31.44M 10-Q · filed 2023-08-07 | -$64.18M 10-Q · filed 2023-08-07 | -$109.75M derived: sum of 3 quarters · filed 2024-03-15 | -$152.58M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-03-31 | -$32.74M 10-Q · filed 2023-05-04 | -$78.31M derived: sum of 2 quarters · filed 2024-03-15 | -$121.14M derived: sum of 3 quarters · filed 2024-03-15 | -$158.54M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2021-12-31 | -$45.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$88.40M derived: sum of 2 quarters · filed 2024-03-15 | -$125.80M derived: sum of 3 quarters · filed 2024-03-15 | -$173.41M 10-K · filed 2024-03-15 | ||
| 2021-09-30 | -$42.82M 10-Q · filed 2022-11-09 | -$80.22M derived: sum of 2 quarters · filed 2022-11-09 | -$127.84M 10-Q · filed 2022-11-09 | -$164.79M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | -$37.40M 10-Q · filed 2022-08-04 | -$85.01M 10-Q · filed 2022-08-04 | -$121.97M derived: sum of 3 quarters · filed 2022-08-04 | -$143.68M derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | -$47.61M 10-Q · filed 2022-05-05 | -$84.56M derived: sum of 2 quarters · filed 2022-05-05 | -$106.28M derived: sum of 3 quarters · filed 2022-05-05 | -$129.88M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2020-12-31 | -$36.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$58.67M derived: sum of 2 quarters · filed 2022-03-09 | -$82.26M derived: sum of 3 quarters · filed 2022-03-09 | -$104.30M 10-K · filed 2022-03-09 | ||
| 2020-09-30 | -$21.72M 10-Q · filed 2021-11-15 | -$45.31M derived: sum of 2 quarters · filed 2021-11-15 | -$67.34M 10-Q · filed 2021-11-15 | -$86.00M derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | -$23.60M 10-Q · filed 2021-08-05 | -$45.63M 10-Q · filed 2021-08-05 | -$64.29M derived: sum of 3 quarters · filed 2021-08-05 | -$80.15M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | -$22.03M 10-Q · filed 2021-05-06 | -$40.69M derived: sum of 2 quarters · filed 2021-05-06 | -$56.56M derived: sum of 3 quarters · filed 2021-05-06 | -$70.59M derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2019-12-31 | -$18.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$34.52M derived: sum of 2 quarters · filed 2021-03-09 | -$48.56M derived: sum of 3 quarters · filed 2021-03-09 | -$54.74M 10-K · filed 2021-03-09 | ||
| 2019-09-30 | -$15.87M 10-Q · filed 2020-11-12 | -$29.90M derived: sum of 2 quarters · filed 2020-11-12 | -$36.09M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$14.03M 10-Q · filed 2020-08-06 | -$20.22M 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | -$6.18M 10-Q · filed 2020-05-07 | |||||
| 2018-12-31 | -$17.41M 10-K · filed 2020-03-12 | |||||
| 2018-09-30 | -$65.00K 10-Q · filed 2019-11-06 | -$75.00K 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |